I think IDH has probably been measured in the Phase III trial by now, because LL measured it in earlier DCVax-Brain trials she discussed. Doubt they’ll miss reporting that, because, although typically only 10% of the total GBM population has IDH-1 mutated tumors, Dr. Liau was well aware of its potential impact on the trial, and they said they would later go back and collect it after the Journal of Translational Medicine article — although Dr. Liau did not think it would have a profound impact on overall trial stats. The plateau Dr. Stupp discusses for idh-1mutated only adds a few more (perhaps four to six) median months (aka: total of 27 months mOS). He is not talking about added years of life with SOC. Really long term survivors with SOC only make up about 3% according to Dr. Fine, and made up 5% or less of the Optune — less If Dr. Stupp had kept following his trial population instead of shutting down data updates.
Idh-1 mutated tends to be proneural, and tends to be less responsive to SOC. It tends to have younger patients who on median live some months longer than other forms of GBM, but not typically longer than three years.
It also, in earlier studies by Dr. Liau and Prins, did not, according to them, respond as well to DCVax-l as say, mesenchymal.
From my cursory review of the clinics added to the trials, I believe there was probably a brief temporary dip in three year survival correlating years after a very large children’s clinic that also handled 18-21 year olds was added to the trial. I do not believe proneural responded to DCVax-l or SOC in that population very often. I think it’s ultimately the primary reason why NWBO and LP are looking at inMune and DCVax-Direct reservoir introduction into the brain.
The IDH-1 mutated population is only about 10% of the global GBM population, but it still needs serious attention, and UCLA, Inmune and NWBO all seem to be very aware of that.
Respect Risk. Conduct Your Own Due Diligence. Manage your assets wisely. Diversify.
